Imunon (IMNN) AI Stock Analysis

• Market Cap: $9.72M
• Dividend Yield: N/A
• Average Volume (3M): 131.31K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.61
• Revenue Growth: N/A
• EPS Growth: 57.97%
• Country: US
• Employees: 25
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.16
• Shares Outstanding: 2,521,206
• 10 Day Avg. Volume: 100,527
• 30 Day Avg. Volume: 131,312
• PEG Ratio: 0.03
• Price to Book (P/B): 2.96
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.67
• Enterprise Value/Market Cap: 1.21
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -4.43
• Enterprise Value/Ebitda: -0.85
• 1Y Price Target: $12.00
• Price Target Upside: 191.26% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: ―

Imunon's financial instability, characterized by negative revenue and cash flow metrics, significantly impacts its overall stock score. Technical indicators suggest caution, with bearish trends and lack of momentum. Though the recent earnings call highlights promising clinical progress, concerns about cash runway and funding remain. Valuation metrics further reflect the stock's risky profile, with a negative P/E ratio and no dividend yield.

Positive Factors

Clinical Progress

The successful Phase 2 study results for Imunon-001 indicate strong clinical progress, enhancing the company's prospects for future product approval and commercialization in oncology.

Regulatory Advancement

FDA's supportive feedback for the Phase 3 study initiation reflects regulatory confidence in Imunon's clinical strategy, potentially accelerating market entry and revenue generation.

Leadership Strength

Dr. Faller's appointment strengthens Imunon's leadership, leveraging his extensive experience to enhance clinical strategy and drive the company's pipeline towards commercialization.

Negative Factors

Financial Instability

Persistent financial challenges, including negative revenue and cash flow, undermine Imunon's operational stability and long-term financial health, necessitating strategic restructuring.

Cash Runway Concerns

Limited cash runway highlights liquidity risks, potentially hindering Imunon's ability to sustain operations and fund ongoing clinical trials without securing additional financing.

High Leverage

High leverage suggests financial strain, limiting Imunon's flexibility to invest in growth opportunities and increasing vulnerability to market fluctuations.

Imunon Business Overview & Revenue Model

Company Description

Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.

How the Company Makes Money

Imunon generates revenue primarily through the development and commercialization of its proprietary therapeutic and vaccine solutions. The company may engage in licensing agreements, where it partners with other pharmaceutical or biotechnology firms to co-develop or distribute its products, thereby earning licensing fees and royalties. Additionally, Imunon may receive funding from government grants or research collaborations, which contribute to its research and development efforts. By advancing its pipeline of candidates through clinical trials and achieving regulatory approvals, Imunon positions itself to earn revenue from product sales, either directly or through strategic partnerships.

Imunon Financial Statement Overview

Summary

Imunon faces significant financial challenges, as indicated by consistently negative revenue, profitability, and cash flow metrics. High leverage and negative returns further exacerbate financial instability. The company needs strategic financial restructuring and improved operational performance to enhance its financial health and investor confidence.

Income Statement

Imunon has consistently reported zero or negative revenue over the past years. Gross profit margins are nonexistent, with significant net losses indicating severe profitability issues. EBIT and EBITDA margins are deeply negative, showing a lack of operational efficiency. There is no evidence of revenue growth, suggesting challenges in achieving market penetration or product commercialization.

Balance Sheet

The company exhibits a relatively high debt-to-equity ratio, indicating reliance on debt financing. Return on Equity (ROE) is negative, reflecting ongoing net losses. The equity ratio shows some equity presence but is overshadowed by continuous financial strain. The balance sheet stability is questionable due to high leverage and negative equity returns.

Cash Flow

Operating cash flow is consistently negative, reflecting poor cash generation from operations. Free cash flow is also negative, indicating insufficient cash to cover capital expenditures. Despite some positive financing and investing cash flow activities, the company's overall cash flow position is weak, raising concerns about liquidity and future operational funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	500.00K	500.00K	500.00K
Gross Profit	-2.66M	0.00	0.00	500.00K	500.00K	500.00K
EBITDA	-13.81M	-17.90M	-19.88M	-31.71M	-20.88M	-21.30M
Net Income	-14.33M	-18.62M	-19.51M	-35.90M	-20.77M	-21.48M
Balance Sheet
Total Assets	8.99M	9.72M	21.92M	43.98M	74.05M	37.53M
Cash, Cash Equivalents and Short-Term Investments	5.25M	5.87M	15.70M	32.75M	49.39M	17.16M
Total Debt	1.10M	1.14M	1.62M	6.27M	6.63M	6.19M
Total Liabilities	4.91M	5.47M	8.53M	14.65M	18.25M	18.92M
Stockholders Equity	4.08M	4.24M	13.39M	29.33M	55.80M	18.61M
Cash Flow
Free Cash Flow	-14.95M	-18.88M	-19.47M	-23.36M	-16.54M	-15.64M
Operating Cash Flow	-14.66M	-18.85M	-19.02M	-23.10M	-16.22M	-15.62M
Investing Cash Flow	-291.89K	9.83M	11.01M	8.28M	-30.12M	7.92M
Financing Cash Flow	9.89M	9.06M	-3.64M	6.72M	54.77M	17.98M

Imunon Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 4.12
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMNN, the sentiment is Neutral. The current price of 4.12 is above the 20-day moving average (MA) of 3.97, below the 50-day MA of 4.61, and below the 200-day MA of 9.23, indicating a neutral trend. The MACD of -0.23 indicates Negative momentum. The RSI at 48.18 is Neutral, neither overbought nor oversold. The STOCH value of 50.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IMNN.

Imunon Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PHIO	42 Neutral	$9.33M	-0.49	-107.58%	―	―	83.95%
IMNN	41 Neutral	$9.72M	-0.28	-233.50%	―	―	57.97%
KZIA	31 Underperform	$12.80M	-0.26	―	―	-98.25%	63.05%
GLTO	29 Underperform	$7.87M	-0.44	-114.81%	―	―	37.42%
RNAZ	27 Underperform	$7.92M	-0.02	-1763.01%	―	―	96.75%

Imunon Corporate Events

Imunon Appoints Dr. Douglas Faller as CMO

On February 18, 2025, IMUNON appointed Dr. Douglas Faller as Chief Medical Officer to lead the company’s clinical strategy, including advancing its lead program IMNN-001 into a Phase 3 trial for advanced ovarian cancer. Dr. Faller brings over 30 years of experience in oncology and immunology, and his appointment is expected to bolster IMUNON’s efforts in progressing its pipeline of non-viral DNA-based immunotherapies, leveraging his expertise to drive clinical programs and potential commercialization.